Sellas Life Sciences is trading at $10.46, up +4.81%, after CEO Angelos Stergiou’s October 19 anniversary post prompted retail speculation about possible upcoming news.
- The post announced no clinical update or timeline.
- The Phase 3 REGAL readout remains a key investor focus, but no confirmed company announcement was identified to explain the move.
- Premarket shares gained as much as 1.5%; current trading volume was unavailable in the provided price context.